The US Food and Drug Administration approved Adzenys-ODT at the end of last week. It is the first new medication of its kind for the treatment of attention-deficit hyperactivity disorder (ADHD).

The Texas-based Neos Therapeutics’ long-acting stimulant medication is approved for treatment for ADHD in children ages six years and older. It is a tablet that disintegrates orally.

ADHD affects nine percent of teens ages 13 to 18, and 4.1 percent of adults in the United States, according to the National Institute of Mental Health.

Statistics vary on how many elementary school age children are affected by the condition, which is marked by difficulties with focus, attention, impulsivity, organizational skills and executive functioning.

The company expects to launch the product and begin shipments to pharmacies in the second quarter of 2016, according to Reuters.